AlphaValue Corporate Services Fundamental Analysis FR
Back to
AlphaValue Corporate Services
This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II

Crossject

CR
Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Some patience (still) required
Target
Upside 232%
Price (€) 3.13
Market Cap (€M) 79.2
Perf. 1W: -2.34%
Perf. 1M: 69.8%
Perf. 3M: 57.2%
Perf Ytd: 9.65%
10 day relative perf. to stoxx600: -9.68%
20 day relative perf. to stoxx600: 80.2%
EPS change18/08/2021

Change in EPS2021 : € 0.18 vs 0.18-0.32%
2022 : € 0.91 vs 0.91-0.32%

We have only integrated the detailed numbers for FY20, which translate into a slightly lower EPS. However, the change is not meaningful given the still very low level of results of the company before its products reach the market.



Updates

29 Mar 22 Earnings/sales releases
FY21: not very meaningful, as expected

17 Dec 21 Financing issue
New financing

24 Sep 21 Earnings/sales releases
H1 21: unsurprising (as usual)

31 Mar 21 Earnings/sales releases
FY20 unsuprising; waiting for more

15 Dec 20 Financing issue
A double bond issue

12345Next
.